Hospital
Alhambra Hospital Medical Center, LP
Alhambra Hospital Medical Center, LP was paid $1.57M by Medicaid between Jan 2018 and Nov 2024, across 84 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 12% of everything it billed.
33Billing provider infoALHAMBRA HOSPITAL MEDICAL CENTER, LP
ALHAMBRA, CA 91801
ALHAMBRA, CA 91801
33aNPI1770612756assigned 03/05/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.57M
24GClaims97,059
24DCodes billed84
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#261 of 410
Median peer was paid$6.90M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MARSH, LINDA controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 672 | $19K | |
| 2019 | 13,970 | $210K | |
| 2020 | 16,589 | $234K | |
| 2021 | 13,904 | $243K | |
| 2022 | 18,183 | $289K | |
| 2023 | 20,208 | $333K | |
| 2024incomplete | 13,533 | $242K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 12% | 5,915 | 5,276 | $195K |
| 0450 | Emergency room services | 9.5% | 6,180 | 5,529 | $149K |
| 70450 | Computed tomography, head or brain; without contrast material | 8.1% | 1,625 | 1,569 | $127K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 7.5% | 1,250 | 1,207 | $119K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.1% | 1,434 | 1,366 | $111K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.0% | 2,652 | 2,478 | $109K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 4.5% | 987 | 941 | $71K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 4.2% | 488 | 474 | $66K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.2% | 2,049 | 1,906 | $50K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.1% | 3,322 | 3,099 | $48K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.7% | 900 | 874 | $43K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.0% | 202 | 199 | $31K |
72 more codes
| 71045 | Radiologic examination, chest; single view | 1.9% | 4,314 | $30K |
| 80053 | Comprehensive metabolic panel | 1.9% | 6,012 | $30K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 1,388 | $28K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 1.8% | 1,840 | $28K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.6% | 1,628 | $25K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 1,573 | $24K |
| 0710 | 1.5% | 288 | $24K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 6,447 | $23K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 488 | $23K |
| 0270 | 1.2% | 3,818 | $20K | |
| 99199 | Unlisted special service, procedure or report | 1.1% | 2,502 | $18K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.0% | 357 | $16K |
| 84484 | <1% | 2,985 | $14K | |
| 83880 | <1% | 821 | $14K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,086 | $12K |
| 99283 | Emergency room visit (moderate) | <1% | 122 | $11K |
| 83690 | <1% | 2,510 | $8K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 794 | $8K |
| 85730 | <1% | 2,604 | $8K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,856 | $7K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,246 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,768 | $6K |
| 87040 | <1% | 747 | $6K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 144 | $6K |
| 81000 | <1% | 3,537 | $6K | |
| 85610 | <1% | 2,665 | $5K | |
| 0360 | <1% | 188 | $5K | |
| J3490 | Unclassified drugs | <1% | 4,927 | $5K |
| 83605 | <1% | 899 | $4K | |
| 81025 | <1% | 1,862 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 611 | $3K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 80 | $3K |
| 83735 | <1% | 643 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 200 | $2K |
| 82150 | <1% | 568 | $2K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 24 | $2K |
| 87428 | <1% | 202 | $2K | |
| 81002 | <1% | 1,140 | $2K | |
| 84703 | <1% | 378 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 104 | $1K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 51 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 68 | $901.81 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 233 | $827.94 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 198 | $766.48 |
| 82550 | <1% | 211 | $686.69 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 85 | $501.51 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 28 | $492.66 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 36 | $417.22 |
| 81015 | <1% | 273 | $388.00 | |
| 80076 | <1% | 116 | $387.60 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 168 | $320.33 |
| 73562 | <1% | 26 | $301.68 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 285 | $267.15 |
| 94762 | <1% | 13 | $254.40 | |
| 0272 | <1% | 606 | $209.59 | |
| 87186 | <1% | 44 | $206.04 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 208 | $200.00 |
| 85379 | <1% | 43 | $179.47 | |
| 87077 | <1% | 44 | $169.80 | |
| 82948 | <1% | 134 | $164.89 | |
| 73630 | <1% | 13 | $156.96 | |
| 93971 | <1% | 12 | $137.83 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 198 | $101.66 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 34 | $97.28 |
| 87280 | <1% | 12 | $84.84 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 42 | $73.56 |
| 86901 | <1% | 53 | $72.89 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 219 | $29.85 |
| 86900 | <1% | 12 | $20.92 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 83 | $20.75 |
| J2704 | Injection, propofol, 10 mg | <1% | 53 | $9.20 |
| 0637 | 0% | 88 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARSH, LINDA (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Ahmc Garfield Medical Center LP | Monterey Park, CA | $17.83M |
| Ahmc Whittier Hospital Medical | Whittier, CA | $15.12M |
| Ahmc Anaheim Regional Medical | Anaheim, CA | $14.21M |
| Ahmc Monterey Park Hospital LP | Monterey Park, CA | $10.85M |
| Ahmc Greater El Monte Community | South El Monte, CA | $9.17M |
| Ahmc San Gabriel Valley Medical | San Gabriel, CA | $6.96M |
| Alhambra Hospital Medical Center, LP | Alhambra, CA | $6.90M |
| Ahmc Seton Medical Center LLC | Daly City, CA | $5.21M |
| Ahmc San Gabriel Valley Medical | San Gabriel, CA | $249K |
| Alhambra Hospital Medical Center, LP | Alhambra, CA | $176K |
| Alhambra Hospital Medical Center, LP | Alhambra, CA | $34K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.